22 results about "Aplastic bone marrow" patented technology

The invention provides an anti-human thrombopoietin antibody AF687, a kit and application thereof. The anti-human thrombopoietin antibody disclosed by the invention can specifically recognize epitopes without glycosylation modification of natural TPO protein, and has relatively high affinity for recombinant TPO protein and specific epitopes of the recombinant TPO protein. Meanwhile, the anti-human thrombopoietin antibody disclosed by the invention can accurately detect the content of human thrombopoietin in serum, is not influenced by heterogeneity of natural protein glycosylation sites, can be used for accurately identifying and diagnosing early aplastic anemia and primary immune thrombocytopenia, and has the advantages that compared with an existing detection reagent, the anti-human thrombopoietin antibody is high in sensitivity and high in sensitivity. The false positive rate can be reduced from 13.9% to 2.7%, and a more accurate detection method is provided for differential diagnosis of the primary immune thrombocytopenia.

Provided herein are methods for promoting or inducing hematopoietic regeneration, or preventing or treating hematopoietic deficiencies, or treating or ameliorating aplastic anemia induced especially by a chemotherapy, or a radiation therapy, comprising administering an effective amount of an adrenoreceptor agonist, especially a selective β2 adrenoreceptor agonist or a selective β3 adrenoreceptor agonist or a nonspecific β adrenoreceptor agonist.

The invention discloses a traditional Chinese medicine composition for treating aplastic anemia and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises active substances, and the active substances are prepared from, by weight, 6-12 parts of semen cuscutae, 6-12 parts of fructus psoraleae, 6-12 parts of fructus ligustri lucidi, 10-14 parts of radix rehmanniae recen, 4-12 parts of radix scutellariae, 4-12 parts of cortex phellodendri, 10-20 parts of poria cocos, 10-30 parts of radix codonopsis, 6-12 parts of rhizoma atractylodis macrocephalae stir-fried with bran and 2-10 parts of radix glycyrrhizae preparata. The traditional Chinese medicine composition is low in cost, high in AA treatment effect and free of toxic and side effects, and has the effects of tonifying kidney, replenishing essence, detoxifying, descending turbidity and the like; the therapeutic effect on AA can be achieved by adjusting glycolysis of macrophages.

The invention provides a traditional Chinese medicine for treating children chronic aplastic anemia, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine for treating children chronic aplastic anemia comprises the following components in parts by weight: 15-30 parts of astragalus membranaceus, 20-30 parts of golden cypress, 10-20 parts of angelica sinensis, 10-20 parts of prepared rehmannia root, 10-15 parts of codonopsis pilosula, 10-15 parts of bighead atractylodes rhizome, 10-15 parts of poria cocos, 10-15 parts of fructus lycii, 10-20 parts of dandelion, 10-20 parts of mint, 10-15 parts of glossy privet fruit, 10-15 parts of eclipta alba, 10-15 parts of fructus psoraleae, 10-15 parts of semen cuscutae, 10-15 parts of caulis spatholobi and 5-10 parts of colla corii asini. , 5-10 parts of tortoise-shell glue, and 5-10 parts of licorice. The radix astragali, the radix codonopsis, the rhizoma atractylodis macrocephalae, the poria cocos and the like have the effects of tonifying qi and spleen and promoting qi and blood biochemical sources; chinese angelica, prepared rehmannia root, donkey-hide gelatin, caulis spatholobi and the like can enrich and nourish blood The fructus lycii, the glossy privet fruit, the herba ecliptae, the fructus psoraleae, the semen cuscutae and the like have the effects of tonifying kidney and replenishing essence, regulating the immune function of the body and improving the hematopoietic microenvironment, so that the chronic aplastic anemia of children is effectively treated, and the levels of hemoglobin, leukocytes, platelets and other blood cells are improved.

The invention provides an anti-human thrombopoietin antibody AF692, a kit and application of the anti-human thrombopoietin antibody AF692. The anti-human thrombopoietin antibody disclosed by the invention can specifically recognize epitopes without glycosylation modification of natural TPO protein, and has relatively high affinity for recombinant TPO protein and specific epitopes of the recombinant TPO protein. Meanwhile, the anti-human thrombopoietin antibody disclosed by the invention can be used for accurately detecting the content of human thrombopoietin in serum, is not influenced by natural protein glycosylation site heterogeneity, and can be used for accurately identifying and diagnosing early aplastic anemia and primary immune thrombocytopenia; and a more accurate detection method is provided for differential diagnosis of the primary immune thrombocytopenia.

The present invention discloses the application of sulforaphane in the preparation of a product for treating aplastic anemia, and belongs to the field of biotechnology. The present invention finds that sulforaphane (SPN) can not only reverse the disease degree of aplastic anemia, but also achieve the purpose of treating AA by inhibiting the occurrence of ferroptosis. Therefore, the use of sulforaphane in the preparation of a product for preventing and treating aplastic anemia must have a good application prospect, and the present invention provides a new solution for the treatment of aplastic anemia.

The invention relates to the technical field of hematopoietic reconstruction, in particular to application of costal cartilage derived stem cells and costal cartilage derived stem cells combined with pluripotent progenitor cells, hematopoietic stem cells or cyclosporine in preparation of a preparation for hematopoietic reconstruction. The costal cartilage derived stem cells (CD45-CD51 +) are derived from costal cartilage and have remarkable ecological niche recovery capability. When the cells are used alone or combined with hematopoietic stem cells and pluripotent progenitor cells, the hematopoietic function can be enhanced. The costal cartilage-derived stem cells are directionally differentiated into important supporting cells forming bone marrow ecological niche, secrete hematopoietic cell factors and protect hematopoietic stem / progenitor cells. In treatment of aplastic anemia, costal cartilage-derived stem cells and cyclosporin A have a synergistic effect, and immune-mediated bone marrow failure is improved through dual mechanisms. According to the technical scheme, the technical problem that the effect of treating bone marrow failure and promoting hematopoietic reconstruction by hematopoietic stem cell transplantation is not ideal is solved, and a new way is opened up for treating bone marrow failure and blood system diseases.

The invention provides a traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition comprises more than 30 Chinese herbal medicines such as radix bupleuri, murraya paniculata, codonopsis pilosula, allium macrostemon and cassia twig. The traditional Chinese medicine composition is mainly used for strengthening the spleen, excreting dampness, promoting intestinal tract movement and recovering normal operation of a nutrient absorption function, regulating normal operation of a digestion and absorption system of a human body and promoting transportation and transformation of the spleen and the small intestine by gradually controlling the pathogenesis of aplastic anemia, and plays a coordination and comprehensive treatment role from regenerated marrow to regenerated blood; and the pathogenesis of aplastic anemia is radically and thoroughly reversed, so that the body achieves the purpose of natural rehabilitation.

The present invention relates to a pharmaceutical composition for treating aplastic anemia containing romiplostim as an active ingredient, which is administered subcutaneously once a week at a dose of 10 μg / kg / week as romiplostim for the first four weeks of administration, and from the fifth week onwards at a dose of more than 10 μg / kg / week up to 20 μg / kg / week as romiplostim.

The invention relates to a construction method of a congenital pure red blood cell aplastic anemia zebrafish model, which comprises the following steps: directionally mutating a bysl gene in a wild type zebrafish embryo to obtain F0 generation zebrafish; mating the F0 generation zebrafish with wild type zebrafish, and screening out positive heterozygote F1 generation zebrafish from the born zebrafish; mating the positive heterozygote F1-generation zebrafish with wild type zebrafish, and screening out positive heterozygote F2-generation zebrafish from the born zebrafish; and hybridizing the male and female positive heterozygote F2-generation zebrafish, and screening positive homozygote zebrafish from the born zebrafish as the congenital pure red blood cell aplastic anemia zebrafish model. The model can simulate the symptoms of the congenital pure red blood cell aplastic anemia, and can be used for mechanism research, drug evaluation and new drug screening of the congenital pure red blood cell aplastic anemia.

The invention relates to the technical field of bioinformatics, and provides an analysis method for treating aplastic anemia (AA) targets by cyclosporine, which comprises the following steps: collecting plasma samples from a preliminary diagnosis patient, a disease stable period patient and a healthy control group; the method comprises the following steps: based on a DIA quantitative proteomics method, analyzing proteins in a plasma sample by adopting a liquid chromatography-mass spectrometer (LC-MS) method, and screening differential expression proteins; carrying out enrichment analysis and pathway analysis on the differential expression protein; verifying the expression levels of the differential expression proteins in different groups by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method to obtain key differential expression proteins; a molecular docking technology is adopted to verify the binding capacity of cyclosporine and the differential expression protein, and the potential of the key differential expression protein as a therapeutic target is determined. Different differential proteins of AA patients and healthy people before and after treatment are successfully obtained, an experimental basis is provided for exploring a mechanism for treating AA by cyclosporine, and possibility is provided for searching a new treatment target.

The present invention provides a rapid, non-invasive, and antibody-free method for identifying AA and MDS based on Raman spectroscopy. This method utilizes the peak intensity of Raman spectra as a biomarker for the preparation of products for predicting or detecting blood disorders. The specificity and significant Raman shifts of the present invention are valuable biomarkers for early disease identification, improving diagnostic efficiency, reducing testing costs, and promoting the rapid and accurate diagnosis of AA and MDS.

The invention discloses a traditional Chinese medicine hemagglutination rehabilitation composition for treating aplastic anemia and a preparation method thereof, and is characterized in that the traditional Chinese medicine hemagglutination rehabilitation composition is synthesized from extracts of morinda officinalis, angelica sinensis, American ginseng, rhizoma polygonati, astragalus membranaceus, cistanche, mulberry, raspberry, fructus alpiniae oxyphyllae, hawthorn, Chinese yam, fructus perillae, jujube, semen cassiae and cordyceps sinensis. Compared with the prior art, the traditional Chinese medicine composition for treating aplastic anemia disclosed by the invention has the advantages that a compound compound of a traditional Chinese medicine extract enters blood cells of a human body, mitochondria in the cells converts the compound into ATP (adenosine triphosphate) to supply energy of cell nucleuses (gene DNA), and the cell nucleuses start to split and start and stimulate bone marrow cell regeneration; the traditional Chinese medicine composition can be used for activating body dormant cells, supplementing hemoglobin and recombining stem cells, providing new blood after cell recombination for human body functions, and restarting a basic hematopoietic function of bone marrow, so that the aim of treating aplastic anemia is fulfilled.

The invention provides a composition for treating qi and blood deficiency and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine. The invention discloses a composition for treating qi and blood deficiency. The composition is prepared from the following raw materials: astragalus membranaceus, salvia miltiorrhiza, codonopsis pilosula, fructus lycii, hairyvein agrimony, caulis spatholobi, radix rehmanniae recen, fried malt, fried rhizoma atractylodis macrocephalae, angelica sinensis, fried endothelium corneum gigeriae galli, wine-processed glossy privet fruit, herba epimedii, coptis chinensis, deer-horn glue, tortoise-shell glue and pseudo-ginseng powder. The composition for treating qi and blood deficiency is prepared from a plurality of traditional Chinese medicinal materials with mild properties, not only can tonify yang qi, essence and blood, but also can treat anemia symptoms such as aplastic anemia and the like, myelosuppression caused by platelet, leucopenia and tumor radiotherapy and chemotherapy, and can treat diseases causing qi and blood deficiency. In addition, the invention further provides a preparation method of the composition for treating the qi and blood deficiency, the preparation method of the composition for treating the qi and blood deficiency not only improves the medicine property of the composition for treating the qi and blood deficiency, but also is simple in process, easy to operate and convenient to master.

This application relates to the field of carbon quantum dot traditional Chinese medicine materials, and particularly to the application of human hair carbon in a hematopoietic reagent for aplastic anemia. The application includes: using human hair carbon quantum dots derived from human hair carbon in the preparation of a hematopoietic reagent for chemotherapy-related anemia. This application uses human hair carbon, a traditional Chinese medicine derived from clinical waste, as the core precursor to prepare human hair carbon quantum dots (CrCi-CDs), and applies CrCi-CDs to the development of a hematopoietic reagent for chemotherapy-related anemia. From the raw material source, preparation process, mechanism of action to clinical transformation of the whole chain, it specifically solves the core defects of high raw material cost and unclear biological toxicity risk when existing chemically synthesized carbon dots are used for the treatment of chemotherapy-related anemia, and at the same time meets the clinical drug safety requirements of patients with chemotherapy-induced aplastic anemia.

The invention provides a traditional Chinese medicine composition for treating aplastic anemia. The traditional Chinese medicine composition is prepared from monarch drugs including astragalus membranaceus, prepared rehmannia roots and hairyvein agrimony, ministerial drugs including lychee seeds, rhizoma bletillae and sliced cornu cervi, adjuvant drugs including peach kernels, carthamus tinctorius, lumbricus, rhizoma wenyujin concisum and rabdosia amethystoides, conductant drugs including liquorice and adjuvant drugs including cassia twigs. According to the traditional Chinese medicine composition, the compatibility thought of taking the bulbophyllum and the lychee seeds as the outline is created for the first time, the bletilla striata is combined with the lychee seeds for promoting the circulation of qi, and the antler slices are used for replenishing essence and benefiting marrow, so that a characteristic scheme of regulating qi and blood and dredging and resuscitation is formed. The composition can regulate the core pathogenesis of qi and blood deficiency, marrow sea insufficiency and blood stasis of aplastic anemia at multiple targets, effectively improves the bone marrow hematopoiesis function, solves the problem that the existing therapy is difficult to consider deficiency and excess inclusion, and provides a brand-new and efficient traditional Chinese medicine treatment choice for aplastic anemia.

The invention belongs to the technical field of medicines, and particularly relates to application of LGALS1 and LGALS3 as targets in preparation of medicines for treating aplastic anemia. The LGALS1 gene and the LGALS3 gene are remarkably and highly expressed in the abnormal activation process of the CD8 + T lymphocyte, and the result of the embodiment shows that the combined inhibitor Thiododigalacside of the Galectin-1 and the Galectin-3 can be competitively combined with a substrate of GAL to inhibit the activity of the Gal-1 and the Gal-3, so that the bone marrow infiltration capacity of the CD8 + T lymphocyte is slowed down, and the progress of AA diseases of mice is delayed. The invention provides a new application of the Galectin-1 and Galectin-3 combined inhibitor Thiododigalactoside, and provides a new drug treatment strategy for the treatment of AA (Acetic Acid).

This invention belongs to the field of animal model technology, specifically relating to a method for constructing an animal model of aplastic anemia and premature ovarian failure (POF) and its application in mesenchymal stem cell therapy. Busulfan and cyclophosphamide were administered intraperitoneally to the animals six times in the following order: first, busulfan was administered three times consecutively, followed by cyclophosphamide three times consecutively, thus establishing an animal model of the dual pathological state of aplastic anemia and POF. Furthermore, based on this animal model, a mesenchymal stem cell therapy based on disease stages was established, achieving significant recovery of ovarian function and providing a reliable technical foundation for clinical translational research on POF in adolescents.

The invention provides a prescription for increasing blood platelets by taking tortoise-plastron glue as a monarch drug and application, and relates to the field of drug preparation. The medicine composition is prepared from the following traditional Chinese medicine decoction pieces by weight: 3g to 36g of radix paeoniae alba, 3g to 36g of fried rhizoma atractylodis macrocephalae, 6g to 50g of fried endothelium corneum gigeriae galli, 3g to 36g of radix salviae miltiorrhizae, 3g to 15g of American ginseng, 3g to 36g of plantain herb, 3g to 36g of circium japonicum, 3g to 30g of tortoise glue, 3g to 25g of honey-fried polygala tenuifolia, 3g to 25g of radix bupleuri and 3g to 60g of mulberry seeds. By treating tooth bleeding, epistaxis and systemic purpura caused by reduction of leukocyte value, erythrocyte value, hemoglobin value and platelet value due to chemotherapy or other reasons of aplastic anemia myelodysplastic syndrome, the traditional Chinese medicine composition has the effects of treating leukocyte, erythrocyte and hemoglobin, removing heat to cool blood, stopping bleeding, enriching blood and generating blood. Moreover, the side effects of chemotherapy can be relieved. The traditional Chinese medicine has safe and stable curative effects, and has the functions of protecting spleen and stomach, protecting liver and kidney, inducing diuresis to reduce edema, filling bone marrow asthenia, soothing nerves

Provided in the present invention are humanized anti-human CD132 monoclonal antibodies and the use thereof. The present invention performs humanized transformation on the basis of monoclonal chimeras 2D4 and 5H10, so as to obtain high-affinity humanized monoclonal antibodies h2D4H4K12 and h5H10H6K4 targeting the human CD132 by means of screening; therefore, without attenuating the antibody activity, the immunogenicity of parental chimeras is reduced, thus reducing the possible risk that medicated patients may generate immune responses on the antibodies. The monoclonal antibodies can be used for prevention, neutralization or treatment of autoimmune diseases related to IL-4, IL-7, IL-9, IL-15 and / or IL-21 cytokines, e.g. systemic lupus erythematosus, rheumatoid arthritis, vitiligo, psoriasis, alopecia areata, inflammatory bowel disease, systemic sclerosis, graft-versus-host disease and aplastic anemia.

The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and / or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and / or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.

A mouth-nose-ear cavity bleeding emergency treatment device for aplastic anemia patients belongs to the technical field of medical apparatus and instruments, and comprises a hemostasis spray tank, a storage cylinder main body, an adjusting ring, a discharge port and a spray irrigation cover main body, the storage cylinder main body is rotatably connected to the bottom end of the hemostasis spray tank, and a groove is formed in the middle of the bottom of the hemostasis spray tank; when the mouth-nose-ear cavity bleeding emergency treatment device for aplastic anemia patients is used, the ultraviolet disinfection lamp and the disinfection ring in the spray irrigation cover body can disinfect and sterilize the surface of the pressing block, and ultraviolet rays can directly destroy DNA structures of microorganisms such as bacteria and viruses. The pressing device is simple in structure, high in killing rate of pathogenic microorganisms on the surface and in gaps of the pressing block, capable of thoroughly removing residual blood, secretions and other pollutants after use, capable of solving the problem that thorough disinfection is difficult in a traditional cleaning mode, and capable of fundamentally reducing the cross infection risk of aplastic anemia patients caused by pressing device pollution. Moreover, the pressing block can press the disinfected tissues for hemostasis, the probability of continuous bleeding of the patient is reduced, and the spray irrigation cover body made of mirror glass is convenient for the patient to quickly and accurately find bleeding points and stop bleeding.